Enhancing Medical Review of ICSRs with Affinity Analysis
During the medical review of Investigational New Drug (IND) SUSARs, FDA mandates sponsors to diligently identify analogous suspected adverse events previously documented and systematically evaluate the current safety report within the context of these previously submitted cases. This analytical process...
continue reading












